health

февраль 19, 2026

FDA reverses course, will review Moderna’s new mRNA flu vaccine

Two weeks ago, the FDA took the rare step of refusing to accept Moderna’s application for its first mRNA flu vaccine. After meeting with the company, the agency has now agreed to review it.

FDA reverses course, will review Moderna’s new mRNA flu vaccine

TL;DR

  • The FDA will now review Moderna's mRNA flu vaccine application.
  • The FDA had previously refused to accept the application.
  • The decision to review was made after a meeting with Moderna.

Two weeks ago, the FDA took the rare step of refusing to accept Moderna’s application for its first mRNA flu vaccine. After meeting with the company, the agency has now agreed to review it.